



Albireo
10 Post Office Square
Suite 502 South
Boston, MA 02109
United States

Visit IR website [↗](#)
Sign-up for Email alerts [↗](#)

NASDAQ: ALBO

Last Trade:	22.24
Trade Time:	4:00 PM ET Sep 22, 2017
Change:	0.08 ↑ (+0.361%)
Day Range	21.71 - 22.26
52-Week Range	12.31 - 37.69
Volume	29,000

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Albireo Pharma is a clinical-stage company focused through its operating subsidiary on the development of therapies for orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo's lead product candidate, A4250, is an ileal bile acid transporter (IBAT) inhibitor in development for pediatric cholestatic liver diseases, initially progressive familial intrahepatic cholestasis (PFIC). Albireo Pharma is headquartered in Boston, Massachusetts and its operating subsidiary is located in Gothenburg, Sweden.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Sep 19, 2017*
[Albireo to Present at Investor Conferences in September](#)
- Sep 5, 2017*
[Albireo to Present at 19th Annual Rodman & Renshaw Global Investment Conference](#)
- Aug 21, 2017*
[Albireo Reports Second Quarter 2017 Financial Results](#)
- Aug 8, 2017*
[Albireo to Present at Wedbush PacGrow Healthcare Conference](#)
- May 30, 2017*
[Albireo Announces Closing of \\$51.9 Million Public Offering Including Exercise of Underwriters' Option to Purchase Additional Shares](#)

Upcoming Events [\[View all \]](#)

- Sep 26, 2017 9:00 AM ET*
[Ladenburg Thalmann Healthcare Conference](#)
- Sep 27, 2017 3:25 PM ET*
[Cantor Fitzgerald Global Healthcare Conference](#)
- Financials** [\[View all \]](#)
 - [Second Quarter Financial Results](#)
 - Mar 27, 2017*
[Annual Report \(10-K\)](#)
 - Apr 21, 2017*
[Proxy Statement \(DEF 14A\)](#)
 - Aug 21, 2017*
[Quarterly Report \(10-Q\)](#)
 - May 11, 2017*
[Quarterly Report \(10-Q\)](#)